- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
OpGen Announces Closing of $12 Million Public Offering
OpGen (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million. As quoted in the press release: “We are very pleased to have completed this offering with both new and existing stockholders, and look …
OpGen (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million.
As quoted in the press release:
“We are very pleased to have completed this offering with both new and existing stockholders, and look forward to continuing the development of our Acuitas AMR Gene Panels, as well as additional efforts to improve patient care and tackle the problem of multidrug antibiotic resistance,” said Evan Jones, chairman and chief executive officer of OpGen. “We expect that the capital from this raise will fund our planned operating activities into 2019 and allows us to focus on executing our growth strategy.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.